Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

2005 ◽  
Vol 23 (1) ◽  
pp. 31-37 ◽  
Author(s):  
John L. Marshall ◽  
Hedy Kindler ◽  
John Deeken ◽  
Pankaj Bhargava ◽  
Nicholas J. Vogelzang ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Phase I Trial ◽  
Kinase Inhibitor ◽  
Neurotrophin Receptor

Acute left ventricular dysfunction induced by a panHER and VEGFR tyrosine kinase inhibitor in a phase I trial

2009 ◽  
Vol 28 (3) ◽  
pp. 350-352 ◽  
Author(s):  
Rastislav Bahleda ◽  
Christophe Massard ◽  
Jean-Charles Soria ◽  
Hassan Izzedine ◽  
Ariel Cohen ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Left Ventricular Dysfunction ◽  
Phase I Trial ◽  
Ventricular Dysfunction ◽  
Kinase Inhibitor ◽  
Left Ventricular ◽  
Vegfr Tyrosine Kinase Inhibitor

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study

2021 ◽  
Author(s):  
Katrina S. Pedersen ◽  
Patrick M. Grierson ◽  
Joel Picus ◽  
A. Craig Lockhart ◽  
Bruce J. Roth ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor

scholarly journals Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors

2011 ◽  
Vol 18 (4) ◽  
pp. 1092-1100 ◽  
Author(s):  
Adil I. Daud ◽  
Smitha S. Krishnamurthi ◽  
Mansoor N. Saleh ◽  
Barbara J. Gitlitz ◽  
Mitesh J. Borad ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Phase I ◽  
Tyrosine Kinase Inhibitor ◽  
Solid Tumors ◽  
Phase I Study ◽  
Kinase Inhibitor ◽  
Advanced Solid Tumors ◽  
Abl Tyrosine Kinase ◽  
Abl Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document